Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
The British Journal of Surgery|October 13, 2015
Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopyJ M Findlay, K M Bradley, E J Maile, et al.
International Journal of Oncology|January 6, 2011
Circulating melanoma cells and survival in metastatic melanomaC Rao, T Bui, M Connelly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2017
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanomaR J Lee, G Gremel, A Marshall, et al.
The British Journal of Surgery|January 18, 2017
Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancerJ M Findlay, K M Bradley, L M Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumorsV M Macaulay, M R Middleton, A S Protheroe, et al.
The British Journal of Dermatology|July 17, 2013
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY studyP Lorigan, M Marples, M Harries, et al.
British Journal of Cancer|May 19, 2011
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancerO A Khan, A D Blann, M J Payne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanomaB W Hancock, K Wheatley, S Harris, et al.
British Journal of Cancer|September 29, 2005
The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western populationR O Illing, J E Kennedy, F Wu, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient ProgrammeF Khan, C Ottensmeier, S Popat, et al.
Pageof 6